SOX2 and neoplasm: In line with this, it was demonstrated that NVP-BEZ-235 (dactolisib), a dual inhibitor of PI3K and mTOR, cooperates with sonidegib in inhibiting the self-renewal capacity of GSCs, in reducing the expression of pluripotency-maintaining factors (e.g., NANOG, POU5F1, and SOX2), and in inhibiting mouse tumor growth, showing superior effects than either drug alone [161].